Author

Anvi Khandelwal

Observed names: A Khandelwal, Khandelwal, Anvi

OpenAlex ID: A5078030732

Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong

2024 · Ava Kwong, Roland Leung, et al. · Oncology and Therapy · 5

Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients

2023 · Raquel Aguiar-Ibáñez, Emilie Scherrer, et al. · BMC Health Services Research · 5

897 Infusion episode-related benefits of pembrolizumab Q6W dosing schedule for patients with melanoma treated in the adjuvant and metastatic settings in the United States (US)

2021 · Raquel Aguiar-Ibanez, Emilie Scherrer, et al. · Journal for ImmunoTherapy of Cancer · 3

EE10 Cost-Effectiveness of Pembrolizumab Plus Chemotherapies for First-Line Treatment in Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer (MTNBC) in France

2022 · O Tredan, L Bensimon, et al. · Value in Health

Works count: 7

Citation count: 13

H-index: 3

I10-index: